DD204945A5 - Verfahren zur herstellung eines komplexes fuer die hemmung der proliferation und migration von tomorzellen - Google Patents

Verfahren zur herstellung eines komplexes fuer die hemmung der proliferation und migration von tomorzellen Download PDF

Info

Publication number: DD204945A5
Authority: DD; German Democratic Republic
Prior art keywords: dsrna; tobramycin; aminoglycoside; double; complex
Prior art date: 1981-11-23

Application number

DD82245159A

Other languages

German (de)

English (en)

Inventor

Richard J Douthart

Walter J Kleinschmidt

Richard M Schultz

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-11-23

Filing date

1982-11-23

Publication date

1983-12-14

1981-11-23 Priority claimed from US06/324,241 external-priority patent/US4400375A/en

1982-11-23 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1983-12-14 Publication of DD204945A5 publication Critical patent/DD204945A5/de

Links

230000005764 inhibitory process Effects 0.000 title claims abstract description 7
230000005012 migration Effects 0.000 title claims abstract description 6
238000013508 migration Methods 0.000 title claims abstract description 6
230000035755 proliferation Effects 0.000 title claims abstract description 6
238000004519 manufacturing process Methods 0.000 title claims 2
108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 100
102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 94
229960000707 tobramycin Drugs 0.000 claims abstract description 55
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims abstract description 37
229940126575 aminoglycoside Drugs 0.000 claims abstract description 31
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 22
229910052698 phosphorus Inorganic materials 0.000 claims abstract description 19
239000011574 phosphorus Substances 0.000 claims abstract description 19
238000000034 method Methods 0.000 claims abstract description 16
229930193140 Neomycin Natural products 0.000 claims abstract description 13
229960004927 neomycin Drugs 0.000 claims abstract description 13
210000004881 tumor cell Anatomy 0.000 claims abstract description 9
XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 claims abstract description 8
229950006334 apramycin Drugs 0.000 claims abstract description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 8
239000000872 buffer Substances 0.000 claims description 16
239000002245 particle Substances 0.000 claims description 3
241000228143 Penicillium Species 0.000 claims 1
230000007935 neutral effect Effects 0.000 claims 1
241000228150 Penicillium chrysogenum Species 0.000 abstract description 8
238000002360 preparation method Methods 0.000 abstract description 5
230000008569 process Effects 0.000 abstract description 3
239000000243 solution Substances 0.000 description 35
102000014150 Interferons Human genes 0.000 description 23
108010050904 Interferons Proteins 0.000 description 23
229940079322 interferon Drugs 0.000 description 23
210000004027 cell Anatomy 0.000 description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
241000282414 Homo sapiens Species 0.000 description 18
210000002966 serum Anatomy 0.000 description 18
239000000203 mixture Substances 0.000 description 16
241000699670 Mus sp. Species 0.000 description 13
239000012458 free base Substances 0.000 description 13
206010028980 Neoplasm Diseases 0.000 description 12
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 11
239000007853 buffer solution Substances 0.000 description 10
230000000694 effects Effects 0.000 description 10
235000002639 sodium chloride Nutrition 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
239000007983 Tris buffer Substances 0.000 description 9
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
210000002540 macrophage Anatomy 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000002609 medium Substances 0.000 description 6
229960005322 streptomycin Drugs 0.000 description 6
238000011282 treatment Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
102000006382 Ribonucleases Human genes 0.000 description 5
108010083644 Ribonucleases Proteins 0.000 description 5
239000002585 base Substances 0.000 description 5
239000006071 cream Substances 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
230000009918 complex formation Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
230000007515 enzymatic degradation Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
229940053050 neomycin sulfate Drugs 0.000 description 4
210000003024 peritoneal macrophage Anatomy 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000008033 biological extinction Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000006210 lotion Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
210000002268 wool Anatomy 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
108010007568 Protamines Proteins 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
239000003070 absorption delaying agent Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920000768 polyamine Polymers 0.000 description 2
-1 polyethylene Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000000344 soap Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
WADQOGCINABPRT-UHFFFAOYSA-N 3-chloro-2-methylphenol Chemical class CC1=C(O)C=CC=C1Cl WADQOGCINABPRT-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000892910 Aspergillus foetidus Species 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000228145 Penicillium brevicompactum Species 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241001136494 Talaromyces funiculosus Species 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229960001192 bekanamycin Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002435 cytoreductive effect Effects 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000008570 general process Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000002799 interferon inducing agent Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
SKKLOUVUUNMCJE-FQSMHNGLSA-N kanamycin B Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SKKLOUVUUNMCJE-FQSMHNGLSA-N 0.000 description 1
229930182824 kanamycin B Natural products 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

DD82245159A 1981-11-23 1982-11-23 Verfahren zur herstellung eines komplexes fuer die hemmung der proliferation und migration von tomorzellen DD204945A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32424381A	1981-11-23	1981-11-23
US06/324,241 US4400375A (en)	1981-11-23	1981-11-23	Tobramycin-double stranded RNA complex suitable for inducing interferon

Publications (1)

Publication Number	Publication Date
DD204945A5 true DD204945A5 (de)	1983-12-14

Family

ID=26984355

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD82245159A DD204945A5 (de)	1981-11-23	1982-11-23	Verfahren zur herstellung eines komplexes fuer die hemmung der proliferation und migration von tomorzellen

Country Status (16)

Country	Link
EP (1)	EP0080357A1 (cs)
AR (1)	AR229715A1 (cs)
AU (1)	AU9036082A (cs)
BG (1)	BG37077A3 (cs)
CA (1)	CA1190492A (cs)
CS (1)	CS836982A2 (cs)
DD (1)	DD204945A5 (cs)
DK (1)	DK519682A (cs)
ES (1)	ES8401986A1 (cs)
GB (1)	GB2110220B (cs)
GR (1)	GR77032B (cs)
IL (1)	IL67316A0 (cs)
NZ (1)	NZ202454A (cs)
PL (1)	PL239178A1 (cs)
PT (1)	PT75879B (cs)
RO (1)	RO85130B (cs)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1170929A (en) *	1965-12-28	1969-11-19	Glaxo Lab Ltd	Antirival Nucleic Acids.
US3582469A (en) *	1968-09-27	1971-06-01	Merck & Co Inc	Production of double-stranded ribonucleic acid
BE790953A (fr) *	1971-11-05	1973-05-03	Beecham Group Ltd	Matiere biologiquement active
GB1440626A (cs) *	1973-05-02	1976-06-23	Farmaceutici Italia

1982
- 1982-11-10 NZ NZ202454A patent/NZ202454A/en unknown
- 1982-11-11 AU AU90360/82A patent/AU9036082A/en not_active Abandoned
- 1982-11-21 IL IL67316A patent/IL67316A0/xx unknown
- 1982-11-22 CA CA000416087A patent/CA1190492A/en not_active Expired
- 1982-11-22 EP EP82306205A patent/EP0080357A1/en not_active Ceased
- 1982-11-22 DK DK519682A patent/DK519682A/da not_active Application Discontinuation
- 1982-11-22 ES ES517581A patent/ES8401986A1/es not_active Expired
- 1982-11-22 PT PT75879A patent/PT75879B/pt unknown
- 1982-11-22 GB GB08233262A patent/GB2110220B/en not_active Expired
- 1982-11-23 CS CS828369A patent/CS836982A2/cs unknown
- 1982-11-23 BG BG058684A patent/BG37077A3/xx unknown
- 1982-11-23 AR AR291381A patent/AR229715A1/es active
- 1982-11-23 GR GR69884A patent/GR77032B/el unknown
- 1982-11-23 RO RO109102A patent/RO85130B/ro unknown
- 1982-11-23 DD DD82245159A patent/DD204945A5/de unknown
- 1982-11-23 PL PL23917882A patent/PL239178A1/xx unknown

Also Published As

Publication number	Publication date
AU9036082A (en)	1983-06-02
EP0080357A1 (en)	1983-06-01
GB2110220B (en)	1985-02-13
RO85130B (ro)	1984-10-30
AR229715A1 (es)	1983-10-31
PL239178A1 (en)	1983-08-01
CS836982A2 (en)	1985-07-16
ES517581A0 (es)	1984-01-01
PT75879B (en)	1986-01-15
BG37077A3 (en)	1985-03-15
CA1190492A (en)	1985-07-16
RO85130A (ro)	1984-09-29
NZ202454A (en)	1985-10-11
PT75879A (en)	1982-12-01
DK519682A (da)	1983-05-24
IL67316A0 (en)	1983-03-31
ES8401986A1 (es)	1984-01-01
GB2110220A (en)	1983-06-15
GR77032B (cs)	1984-09-04

Legal Events

Date	Code	Title	Description
1992-05-07	NAB	Public notice for inspection of provisional exclusive patent accord. to par 17/1 dd-patg.

Publication	Publication Date	Title
DE60130976T2 (de)	2008-07-17	Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
DE3751258T2 (de)	1995-09-07	Mikrokristalle, die eine aktive Substanz mit phospholipidischer Affinität enthalten und mindestens ein Phospholipid, Verfahren zur Herstellung.
DE60223670T2 (de)	2008-03-06	Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
DE69318033T2 (de)	1998-10-22	Antitumorzusammensetzungen enthaltend taxanderivate
DE69329073T2 (de)	2001-01-18	In liposomen verkapseltes taxol und verwendungsverfahren
DE68920656T2 (de)	1995-05-18	Verwendung vpn Adenosin-5'-phosphate in der Behandlung von Krebscachexia.
DE69530124T2 (de)	2004-02-05	Liposomale antibakterielle zusammensetzung mit geringer festigkeit
DE68914154T2 (de)	1994-10-20	In liposomen verkapselte vinca-alkaloide und deren verwendung zur tumorbekämpfung.
DD148951A5 (de)	1981-06-17	Verfahren zur herstellung virozider aminderivate
DE69008729T2 (de)	1994-09-08	Verfahren zur herstellung einer öl-in-wasser-emulsion eines wirkstoffes.
DE60012230T2 (de)	2005-08-04	Verwendung einer oligosaccharide enthaltenden dermatologischen zubereitung zur behandlung von hauterkrankungen
DE69215999T2 (de)	1997-07-03	Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs
DE69420859T2 (de)	2000-01-05	Multilamellare liposomformulierungen, die einen arachidsäuremetaboliten enthalten
DE102010028365A1 (de)	2011-11-03	Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
DE68905994T2 (de)	1993-08-05	Koloniestimulierungsfaktor-gelatinkonjugate.
DE3115080A1 (de)	1982-02-25	Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
EP0705601A1 (de)	1996-04-10	Lösungen von Anthrachinonen zur parenteralen Applikation
DE3779562T2 (de)	1993-01-21	Golgi-alpha-mannosidase ii-inhibitoren enthaltende zubereitungen.
EP2047855B1 (de)	2010-08-25	Antitumorale, antibakterielle und antivirale pharmazeutische zusammensetzung (varianten)
EP0493662B1 (de)	1995-12-06	Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge
DE69121551T2 (de)	1997-01-02	Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
DE3825374C2 (cs)	1990-06-28
CH643459A5 (de)	1984-06-15	Mikrobielles zellwandgeruest mit adjuvans- und antitumorwirkung enthaltende, verfestigte pharmazeutische zubereitung und ihre herstellung.
DD204945A5 (de)	1983-12-14	Verfahren zur herstellung eines komplexes fuer die hemmung der proliferation und migration von tomorzellen
DE69417169T2 (de)	1999-07-22	Antineoplastische pharmazeutische Zusammensetzung enthaltend ein Fumagillolderivat und einen Platinkomplex